What Does Fiasp Cost in 2026?

Fiasp is the brand name for a faster-acting formulation of insulin aspart, manufactured by Novo Nordisk and FDA-approved on September 29, 2017 (NDA 208751). Novo Nordisk added niacinamide (vitamin B3) and L-arginine to the same insulin aspart molecule found in NovoLog, which speeds the drug's appearance in the bloodstream to approximately 2.5 minutes after injection, faster than standard NovoLog. Fiasp is approved for adults and children with type 1 or type 2 diabetes and can be dosed at the start of a meal or up to 20 minutes after starting to eat, unlike older mealtime insulins that require dosing 15 to 30 minutes beforehand. Fiasp is also FDA-approved for use in insulin infusion pumps.

Novo Nordisk sets Fiasp's wholesale list price at approximately $495 for a 30-day supply in 2026, the same benchmark CMS used when negotiating Fiasp's Medicare price under the Inflation Reduction Act. Cash-pay patients without insurance or a discount card typically pay $340 to $400 for a single 10 mL vial at full retail, though SingleCare and GoodRx-type discount cards bring that down to roughly $63 to $78 per vial at major chains including Kroger, Costco, Walgreens, and CVS. What you actually pay depends heavily on whether you have Medicare, commercial insurance with the Novo Nordisk savings card, or no insurance and qualify for the manufacturer's income-based Patient Assistance Program. This guide breaks down the real 2026 numbers by coverage type. Patients comparing insulin brands should also review the NovoLog cost guide, since NovoLog and Fiasp share the same negotiated Medicare price and the same $35 monthly cap but differ in onset speed and formulation.

CMS selected NovoLog and Fiasp together as a single qualifying drug for the first round of Medicare price negotiation under the Inflation Reduction Act of 2022, because both products share the same active moiety, insulin aspart, and the same manufacturer. The negotiated Maximum Fair Price of $119 for a 30-day supply took effect January 1, 2026, a 76 percent cut from the $495 pre-negotiation list price. Separately, two biosimilar insulin aspart products, Merilog (Sanofi) and Kirsty (Biocon Biologics), reached the market in 2025, but both were approved as biosimilars to NovoLog specifically, not to Fiasp. Patients using Fiasp for its faster onset who want a lower-cost biosimilar option would need to switch to NovoLog, or a NovoLog biosimilar, under a prescriber's guidance, since the pharmacokinetic profile differs from Fiasp's niacinamide-accelerated formulation. Patients with low income who cannot afford Fiasp should also review Medicaid income limits to determine if Medicaid coverage applies.

What Fiasp Costs by Point of Pay (2026)

The price you pay depends almost entirely on WHERE you pay. The same fiasp can cost many times more at a hospital than at your local pharmacy:

Why Hospitals Charge So Much

Fiasp rarely appears as a primary line item on a hospital bill because most patients self-inject it at home before meals. When Fiasp does show up on an inpatient itemized bill, usually because a patient's own supply was used during a stay or the hospital pharmacy dispensed a partial vial, the facility charge can run 5 to 15 times the retail vial price. A single 10-unit dose that costs well under $2 at the Medicare ASP rate can appear on a hospital bill at $50 to $150 or more once nursing administration and pharmacy handling fees are layered on top.

Three structural factors explain the markup. First, hospital chargemasters set prices independent of acquisition cost, commonly applying a multiplier of 3 to 10 times what the facility paid. Second, clinically administered insulin is billed under HCPCS code J1815 (per 5 units) or J1817 (per 50 units, pump supply), and facilities frequently add administration and handling fees on top of the drug charge itself. Third, some hospitals bill for an entire new vial per patient even when only a small fraction was used during the stay. If a hospital bill shows Fiasp priced above $50 per unit, request an itemized breakdown and compare it against the 2026 Medicare Part B ASP rate of roughly $12 per unit under J1815.

HCPCS J-Codes: What Appears on Your Bill

Fiasp administered in a clinical setting, including hospital infusion or a Part B-covered insulin pump, is billed under HCPCS Level II J-codes. These codes appear on hospital outpatient claims, physician office claims, and Medicare Part B claims. Self-administered Fiasp injected at home is billed under Medicare Part D, not under J-codes.

Patient Assistance Programs

Fiasp's cash list price runs about $495 for a 30-day supply in 2026, and a single vial costs $340 to $400 at full retail without a discount. Novo Nordisk operates programs that can cut that cost dramatically depending on your insurance status and income. Commercially insured patients should use the Novo Nordisk savings card first. Medicare beneficiaries and uninsured patients should apply to the NovoCare Patient Assistance Program.

Medicare Part D Coverage for Fiasp

Fiasp is a Medicare Part D drug. Under the Inflation Reduction Act of 2022, all covered insulins, including Fiasp and NovoLog, are capped at $35 per month in out-of-pocket cost under Medicare Part D, effective since January 1, 2023. That cap overrides your plan's deductible, coinsurance, and formulary tier. In 2026, CMS's negotiated Maximum Fair Price of $119 for a 30-day supply of Fiasp means most Medicare patients pay the lesser of $35 or 25 percent of $119, approximately $30 per month.

Medicare Part D covers Fiasp for type 1 and type 2 diabetes management. Most Part D and Medicare Advantage plans list Fiasp at Tier 3 or Tier 4, but the $35 monthly insulin cap overrides tier-based cost sharing. Prior authorization is common when a plan already covers standard NovoLog and wants documentation of why the faster-acting Fiasp formulation is medically necessary. Medicare beneficiaries who still cannot afford the $35 cap may qualify for Extra Help, the Low Income Subsidy, which can reduce cost sharing to $0 or near $0. Check eligibility at medicare.gov or by calling 1-800-MEDICARE.

Patients using an insulin pump that delivers Fiasp through continuous subcutaneous infusion may have their insulin billed under Medicare Part B's durable medical equipment benefit rather than Part D, when the pump itself is covered under Part B. In that scenario, the $35 monthly insulin cap does not apply. Instead, Medicare Part B covers 80 percent of the approved amount after the $283 annual Part B deductible in 2026, leaving the patient responsible for the remaining 20 percent coinsurance. Ask your endocrinologist or diabetes educator which benefit covers your pump insulin to avoid a billing error.

Common Fiasp Billing Errors

Patients billed for Fiasp above $35 per month on Medicare Part D, or above $100 per vial in an outpatient setting, should check for these issues before paying:

• Fiasp billed as NovoLog or NovoLog billed as Fiasp on a pharmacy claim. The two products share the same active ingredient but have different NDC numbers and different formulary placements at some plans. Confirm the dispensed product matches your prescription.
• Copay charged above $35 per month for Fiasp on Medicare Part D. The IRA insulin cap of $35 per month has applied since January 1, 2023, and no Part D plan may charge more for any covered insulin, including Fiasp.
• Prior authorization denial not appealed. Plans sometimes require documentation that standard NovoLog was tried first before covering Fiasp's faster-acting formulation. Denials are not final until the appeal process is exhausted.
• Insulin billed under Part B code J1815 for home self-injection, which should be billed under Part D instead. Self-administered Fiasp at home is always a Part D claim.
• Manufacturer savings card not applied at the pharmacy counter despite eligibility. Ask the pharmacist to rerun the claim using the Novo Nordisk savings card BIN and PCN numbers.
• Hospital bill showing per-unit Fiasp charges of $50 to $150 when the 2026 Medicare ASP under J1815 is approximately $12 per unit. Request an itemized bill and compare line items to the ASP benchmark.

Frequently Asked Questions